Using Innovation-Corps (I-Corps™) Methods to Adapt a Mobile Health (mHealth) Obesity Treatment for Community Mental Health Settings.

Autor:	Haddad R; Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States., Badke D'Andrea C; Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States., Ricchio A; Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States., Evanoff B; Center for Healthy Work, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, United States., Morrato EH; Parkinson School of Health Sciences and Public Health, Loyola University of Chicago, Chicago, IL, United States.; Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, United States., Parks J; National Council for Mental Wellbeing, Washington, DC, United States., Newcomer JW; Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States.; Thriving Mind South Florida, Miami, FL, United States., Nicol GE; Healthy Mind Lab, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in digital health [Front Digit Health] 2022 May 27; Vol. 4, pp. 835002. Date of Electronic Publication: 2022 May 27 (Print Publication: 2022).
DOI:	10.3389/fdgth.2022.835002
Abstrakt:	Background: We employed Innovation Corps (I-Corps™) methods to adaptation of a mobile health (mHealth) short-message-system (SMS) -based interactive obesity treatment approach (iOTA) for adults with severe mentall illness receiving care in community settings. Methods: We hypothesized "jobs to be done" in three broad stakeholder groups: "decision makers" (DM = state and community clinic administrators), "clinician consumers" (CC = case managers, peer supports, nurses, prescribers) and "service consumers" (SC = patients, peers and family members). Semistructured interviews ( N = 29) were recorded and transcribed ver batim and coded based on pragmatic-variant grounded theory methods. Results: Four themes emerged across groups: education, inertia, resources and ownership. Sub-themes in education and ownership differed between DM and CC groups on implementation ownership, intersecting with professional development, suggesting the importance of training and supervision in scalability. Sub-themes in resources and intertia differed between CC and SC groups, suggesting illness severity and access to healthy food as major barriers to engagement, whereas the SC group identified the need for enhanced emotional support, in addition to pragmatic skills like menu planning and cooking, to promote health behavior change. Although SMS was percieved as a viable education and support tool, CC and DM groups had limited familiarity with use in clinical care delivery. Conclusions: Based on customer discovery, the characteristics of a minimum viable iOTA for implementation, scalability and sustainability include population- and context-specific adaptations to treatment content, interventionist training and delivery mechanism. Successful implementation of an SMS-based intervention will likely require micro-adaptations to fit specific clinical settings. Competing Interests: BE has received funding from the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC). EM has received grant support from the National Institutes of Health (NIH) and the CDC and has consulted for the U.S. Food and Drug Administration (FDA) and Eli Lilly and Company. JP has participated in Advisory panels or consulted with Merck, Boehringer-Ingelheim, Lundbeck, Otsuka, and Janssen. JN has participated in advisory panels or consulted with Merck, Boehringer-Ingelheim, Lundbeck, Otsuka, and Janssen; has received grant support from the NIH and the Substance Abuse and Mental Health Services Administration (SAMHSA); has served as a consultant for Alkermes, Inc., Intra-cellular Therapies, Inc., Sunovion and Merck; and served on a Data Safety Monitoring Board for Amgen. GN has received grant support from the NIH, the Barnes Jewish Hospital Foundation, the McDonnell Center for Systems Neuroscience, and Usona Institute (drug only), and has served as a consultant for Alkermes, Inc., Otsuka and Sunovion. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Haddad, Badke D'Andrea, Ricchio, Evanoff, Morrato, Parks, Newcomer and Nicol.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu